GEHC
HealthcareGE HealthCare
Price Chart
Market Data
Financials
XBRL · SEC EDGAR2021–2025(5yr)| Metric | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025Latest | YoY |
|---|---|---|---|---|---|---|
| Revenue | $17.6B | $18.3B | $19.6B | $19.7B | $20.6B | +4.8% |
| Gross Profit | $7.2B | $7.2B | $7.9B | $8.2B | $8.2B | +0.5% |
| Gross Margin | 40.8% | 39.1% | 40.5% | 41.7% | 40.0% | -1.7pp |
| Operating Income | $2.8B | $2.5B | $2.4B | $2.6B | $2.8B | +5.3% |
| Operating Margin | 15.9% | 13.8% | 12.5% | 13.3% | 13.4% | +0.1pp |
| Net Income | $2.2B | $1.9B | $1.6B | $2.0B | $2.1B | +4.6% |
| Net Margin | 12.8% | 10.4% | 8.0% | 10.1% | 10.1% | -0.0pp |
| EPS (Diluted) | $4.95 | $4.22 | $3.03 | $4.34 | $4.55 | +4.8% |
1. THE BIG PICTURE
GE HealthCare is betting that the future of medicine lies in the "unique combination" of imaging hardware and pharmaceutical diagnostics (10-K Item 1). While it maintains a massive global footprint and a deep moat through its 8,900 field engineers, GE HealthCare is currently a lower-margin, cash-burning outlier compared to its more specialized medical technology peers. The central challenge for management is whether its "Heartbeat" operational system can translate high-tech AI integration into the consistent profitability and cash flow that its competitors already enjoy.
2. WHERE THE RISKS HIT HARDEST
GE HealthCare’s Service Infrastructure—a key competitive moat providing recurring revenue through 8,900 engineers—is directly threatened by "right-to-repair" legislation (10-K Item 1, Risks). These laws empower independent service organizations to compete for lucrative service contracts, potentially eroding a core revenue stream that management relies on to offset the volatility of capital equipment sales.
Furthermore, GE HealthCare’s Global Reach, serving 160 countries, is increasingly a liability due to geopolitical and trade instability (Risks). Management specifically cited 2025 U.S. tariffs on global imports as a material threat to profitability. While the CFO noted that GE HealthCare "significantly mitigated" these impacts in the most recent quarter, the reliance on single-source suppliers for critical materials like helium and iodine means any further trade friction could lead to production delays that its global scale cannot easily circumvent (8-K, Risks).
3. WHAT THE NUMBERS SAY TOGETHER
(XBRL) The financial data reveals a company growing its top line but struggling to protect its bottom line. In the fourth quarter of 2025, revenue grew 7.1% to $5.7 billion, yet net income fell to $589 million from $720 million a year earlier (8-K). This divergence is largely driven by the Pharmaceutical Diagnostics (PDx) segment, which surged 22.3%, while the Patient Care Solutions (PCS) segment saw an organic decline of 1.1%.
While GE HealthCare’s 40.5% gross margin is the lowest in its peer group, it remains exceptional for a company with such a heavy hardware mix. However, the more pressing concern is efficiency: GE HealthCare reports a free cash flow (FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders) margin of -0.5%, ranking 6th of 6 among peers (Peer Benchmarking). This negative FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders stands in stark contrast to leaders like Danaher (20.1%) and Boston Scientific (18.3%). Short interest currently sits at 2.9% of the float, suggesting that while sentiment is not overwhelmingly bearish, investors remain cautious about GE HealthCare's ability to convert revenue into cash (Yahoo Finance).
4. IS IT WORTH IT AT THIS PRICE?
GE HealthCare appears attractively valued for investors who believe management can meet its 2026 targets.
- At a 13.2x Forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations, the market is pricing in ~3.4% long-term growth (CAPM analysis).
- This is a 26% discount to the peer median of 17.9x (Peer Benchmarking).
- GE HealthCare's 2026 organic revenue growth guidance of 3.0% to 4.0% and projected adjusted EPSEPSEarnings Per Share — the company's net profit divided by its share count; the most common per-share profitability metric growth of up to 12.3% suggest that the business is capable of exceeding what is currently baked into the price (8-K).
However, the discount is justified by GE HealthCare's negative FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders margin and its lower net margin (9.9%) relative to peers like Boston Scientific (14.2%). If growth were to slow to a GDP-pace of 2.5%, the justified multiple would fall to 11.8x, representing roughly 11% downside (CAPM analysis). The investment case rests entirely on whether the "Heartbeat" system can deliver the 50 to 80 basis points of margin expansion promised for 2026.
5. WHAT WOULD CHANGE THIS VIEW?
- Constructive if GE HealthCare reports a positive Free Cash Flow margin in upcoming quarters, signaling that the "Heartbeat" productivity initiatives are successfully converting revenue into spendable cash.
- Cautious if the Patient Care Solutions (PCS) segment continues its organic decline, suggesting that GE HealthCare is losing ground in hospital monitoring and life support markets to more nimble competitors.
- Cautious if new U.S. tariffs are enacted in 2026, as management has already identified trade policy as a primary driver of cost volatility.
6. BOTTOM LINE
Structural Advantage: A massive installed base of imaging hardware integrated with a proprietary pharmaceutical diagnostics supply chain and a global network of 8,900 service engineers.
Bottom Line: GE HealthCare is a scale-driven value play that is attractively priced, provided it can solve its cash-flow deficit and navigate a worsening global trade environment.
1. Top 5 Material Risks
- Geopolitical and Trade Instability: GE HealthCare faces material impacts to profitability and cash flows from global tariffs, specifically citing 2025 U.S. tariffs on global imports and retaliatory measures from other countries.
- Competitive Pricing and Market Share: Rapidly evolving technology and the emergence of new market entrants, including startups and established technology firms, force GE HealthCare to lower prices or risk losing market share.
- Independent Service Organizations (ISOs): Legislative and regulatory shifts, such as "right-to-repair" laws and copyright exemptions in the U.S., empower third-party repair companies to compete for service contracts, threatening a core revenue stream.
- Supply Chain and Single-Source Dependencies: Reliance on single- or sole-source suppliers for critical components and raw materials—such as helium, iodine, and rare earth minerals—exposes GE HealthCare to production delays and price volatility.
- Digital and AI Integration: Substantial R&DR&DResearch & Development — spending on creating new products or technologies investment in AI, cloud, and edge computing may fail to generate sufficient revenue or attract customers if GE HealthCare cannot successfully navigate stringent data privacy regulations and cybersecurity threats.
2. Company-Specific Risks
- Trademark License Agreement: GE HealthCare does not own the "GE" brand; termination of the Trademark License Agreement with GE would force a corporate name change and expensive, disruptive rebranding efforts.
- Postretirement Benefit Liabilities: GE HealthCare carries significant pension, healthcare, and life insurance obligations that are subject to actuarial assumptions; volatility in financial markets or interest rates could cause these liabilities to exceed current estimates.
- China Procurement Policies: Government-run procurement systems in China, including volume-based procurement and restrictions on the number of invoices allowed in distribution chains, create unique challenges for maintaining geographic reach and sales volume.
- Spin-Off Tax Indemnification: Under the Tax Matters Agreement with GE, GE HealthCare could be liable for significant taxes and related expenses if the spin-off is determined to be a taxable transaction due to breaches of representations or covenants.
3. Regulatory/Legal Risks
- Anti-Corruption and Anti-Bribery: GE HealthCare is subject to the FCPA and UKBA; investigations into healthcare sector corruption in China, Brazil, Mexico, and Russia pose risks of civil or criminal sanctions and exclusion from government programs.
- Product Liability: As a manufacturer of medical devices and radiopharmaceuticals, GE HealthCare faces ongoing litigation risks regarding product defects, misdiagnosis, or failure to warn, which may not be fully covered by insurance.
- Government Contracting: Failure to comply with the Federal Acquisition Regulation, the False Claims Act, or the Anti-Kickback Statute can lead to contract termination, debarment from government work, and treble damages.
- Data Privacy: Global regulations regarding the storage and transfer of sensitive patient data, including "protected health information," impose high compliance costs and potential fines for security breaches.
4. Financial Impact Map
Global Tariffs → Profitability and Cash Flows → Material impact on financial results in 2025 due to bilateral U.S.-China tariffs and U.S. tariffs on global imports. Competitive Pricing Pressures → Revenue and Margins → Potential for lower prices and loss of market share in rapidly evolving technology markets. Independent Service Organizations → Services Revenue → Increased competition for service contracts and potential for higher compliance costs related to safety and quality. Single-Source Supply Disruptions → Cost of Goods Sold → Increased costs and material delays resulting from the need to qualify replacement suppliers or redesign products. Postretirement Benefit Liabilities → Earnings and Equity → Volatility in discount rates and plan asset returns can lead to significant reductions in equity and increased pension/healthcare costs.
Recent Filings
| Form | Filed | Period |
|---|---|---|
| 8-K | Feb 2026 | — |
| 10-K | Feb 2026 | Dec 2025 |
| 10-Q | Oct 2025 | Sep 2025 |
| 14A | Apr 2025 | — |
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
GE HealthCare receives FDA 510(k) clearance for Photonova Spectra photon-counting CT system
- ▸Received FDA 510(k) clearance for Photonova Spectra photon-counting CT system
- ▸Share price declined 11.2% over the last 30 days
- ▸1-year total shareholder return down 10.14% to $71.18
- ▸Fair value estimated at $93.47 per share by market narrative
- ▸Tariffs and China regulatory uncertainty identified as key margin risks
GE HealthCare receives FDA 510(k) clearance for Photonova Spectra photon-counting CT system
- ▸Received FDA 510(k) clearance for Photonova Spectra photon-counting CT system
- ▸Launched integrated cardiology platform featuring AI-enabled imaging and ECG fleet management
- ▸Projects $23.7B revenue and $2.7B earnings by 2029
- ▸Requires 4.8% annual revenue growth to meet long-term financial targets
- ▸Ongoing risks include tariff impacts, China exposure, and free cash flow pressure
Pulsenmore FY25 Revenue $12.5M, Up 374% YoY; Net Loss Narrows to $5M
- ▸FY25 revenue $12.5M, up 374% YoY from $2.6M
- ▸Net loss narrowed to $5M from $10M in 2024
- ▸Recognized $9.6M one-time revenue from GE Healthcare settlement
- ▸Total liquid assets $21.7M as of December 31, 2025
- ▸Secured FDA clearance for remote-use prenatal ultrasound in the U.S.
GE HealthCare receives FDA 510(k) clearance for Photonova Spectra photon-counting CT system
- ▸Photonova Spectra receives FDA 510(k) clearance for U.S. market
- ▸Features proprietary Deep Silicon detector technology with 8-bin energy resolution
- ▸Enables ultra-high definition spatial and spectral imaging for precise tissue visualization
- ▸Part of company's $5.1B innovation investment portfolio
- ▸New technology expected to contribute 1-2% to total revenue growth
GEHC acquires Intelerad for $2.3B to expand cloud-first AI imaging platform
- ▸Acquired Intelerad for $2.3 billion using cash and debt
- ▸Intelerad projected to generate $270 million revenue in first full year
- ▸90% of Intelerad revenue derived from recurring sources
- ▸Targeting adjusted EBITDA margins exceeding 30%
- ▸Expands GEHC footprint into high-growth ambulatory and specialty care settings
GE HealthCare completes $2.3B acquisition of medical imaging software provider Intelerad
- ▸Acquired Intelerad for $2.3 billion in cash
- ▸Estimated first-year revenue contribution of $270 million
- ▸Recurring revenue mix for Intelerad is approximately 90%
- ▸Expands enterprise imaging footprint into ambulatory and teleradiology settings
- ▸Integrates cloud-first and AI-enabled software into existing imaging portfolio
GE HealthCare Middle East exposure under 5%, prioritizes supply chain resiliency and logistics
- ▸Middle East business exposure confirmed at less than 5% of total revenue
- ▸Manufacturing presence in Israel includes PET, spec devices, and ultrasound output
- ▸Logistics focus on maintaining inventory outside conflict zones to ensure continuity
- ▸2024 tariff impact expected to be lower than the $250M recorded in 2023
- ▸Management cites pricing actions and productivity initiatives to offset potential energy cost inflation